Amgen Inc. (AMGN)
Amgen Inc. is a Healthcare company in the S&P 500, the Dow 30 and the Nasdaq 100, with a market capitalization of about $227.9 billion as of October 1, 2026.
- Ticker
- AMGN · Nasdaq
- Sector
- Healthcare
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- Market cap
- $227.9 billion
- Employees
- 31,500
- Headquarters
- Thousand Oaks, CA
- Fiscal year end
- December 31
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Financial statements
Nvevo shows Amgen Inc.'s income statement, balance sheet, cash flow statement and key ratios as reported in its 10-K and 10-Q filings with the SEC, annually and quarterly, alongside price history, recent news and fair value models.
Other Healthcare companies
- Eli Lilly and Company (LLY)
- Johnson & Johnson (JNJ)
- AbbVie Inc. (ABBV)
- Merck & Co., Inc. (MRK)
- UnitedHealth Group Incorporated (UNH)
- Thermo Fisher Scientific Inc. (TMO)
- Gilead Sciences, Inc. (GILD)
- Abbott Laboratories (ABT)
Research another company · Market map · Stock screener · Compare companies